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Abstract
The extracellular matrix (ECM) creates the microenvironment of the tissue; an altered ECM in the asthmatic airway may be central in airway
inflammation and remodelling. Tumstatin is a collagen IV-derived matrikine reduced in the asthmatic airway wall that reverses airway inflamma-
tion and remodelling in small and large animal models of asthma. This study hypothesized that the mechanisms underlying the broad asthma-
resolving effects of tumstatin were due to autocrine remodelling of the ECM. Neutrophils and endothelial cells were seeded on decellularized
ECM of non-asthmatic (NA) or asthmatic (A) airway smooth muscle (ASM) cells previously exposed to tumstatin in the presence or absence of
a broad matrix metalloproteinase inhibitor, Marimastat. Gene expression in NA and A ASM induced by tumstatin was assessed using RT-PCR
arrays. The presence of tumstatin during ECM deposition affected neutrophil and endothelial cell properties on both NA and A ASM-derived
matrices and this was only partly due to MMP activity. Gene expression patterns in response to tumstatin in NA and A ASM cells were different.
Tumstatin may foster an anti-inflammatory and anti-angiogenic microenvironment by modifying ASM-derived ECM. Further work is required to
examine whether restoring tumstatin levels in the asthmatic airway represents a potential novel therapeutic approach.
Keywords: airway smooth muscle extracellular matrix angiogenesis asthma collagen IV
Introduction
Altered ECM composition is a characteristic feature of airway wall
remodelling and cardinal to the pathophysiology of asthma [1, 2]. The
ECM contributes to the microenvironment, which governs cell beha-
viour, activity, gene transcription and protein expression [2, 3]. This
microenvironment regulates the behaviour and movement of cells
entering airway tissues, including inflammatory cell influxes during
inflammation and endothelial cells during angiogenesis. The airway
ECM in asthma has been implicated in airway hyper-responsiveness
(AHR), airway thickening, augmented muscle mass, chronic
inflammation and increased angiogenesis [4, 5], of which the latter
two are the focus of this study.
A distinctive feature of severe asthma is chronic inflammation.
Many patients with asthma experience a T-helper type 2-mediated
response primarily driven by eosinophils [6, 7], which is effectively
suppressed by regular use of inhaled corticosteroids (ICS) [8, 9].
However, a small subsets of patients (5–10%) are resistant to ICS
[10, 11], suffer higher morbidity and mortality, and contribute to the
majority of the economic burden associated with asthma [12]. Severe
asthma features predominately neutrophilic airway inflammation [7,
13, 14]. To date, little attention has been paid to the potential of the
asthmatic airway ECM microenvironment as an anti-inflammatory
therapeutic tool.
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Airway remodelling is a multifactorial and complex process for
which the development and persistence may be enhanced by the
increased number, size and density of blood vessels. Uninhibited
blood vessel expansion promotes tissue dysfunction and uncontrolled
cell growth [15] and has been correlated to AHR in asthma [16, 17].
Blood vessel growth is regulated by a balance of pro- and anti-angio-
genic mediators. Many ECM proteins (including fibronectin, collagen
I, collagen IV and thrombospondin) contribute to the maintenance of
this balance through their respective pro- and anti-angiogenic proper-
ties [4]. The dysregulation of these matrix proteins in the asthmatic
airway [18, 19] may be one means by which the angiogenic balance
is shifted allowing for excessive vascular expansion.
The composition and organization of the ECM microenviron-
ment are tightly regulated in normal tissues [20, 21]. Secretion
and deposition of ECM proteins are balanced by degradation of
matrix filaments by endogenous proteases such as MMPs. In
addition, the ECM contributes to the autocrine regulation of these
proteases, through direct interactions with cellular surface recep-
tors and via matrikines. Matrikines are bioactive ECM fragments
which, once released from their parent compound, regulate cellular
metabolism to influence ECM deposition and degradation [2, 20].
One matrikine of significance in asthma is tumstatin, an anti-
angiogenic fragment of the collagen IV a3 subunit [22], which is
a VEGF antagonist [23]. Compared to the airways of healthy indi-
viduals tumstatin levels are reduced 18-fold in asthmatic airways
[19]. Furthermore, administration of tumstatin in large and small
animal models of airways disease decreased airway vascularity,
reduced airway inflammation and improved AHR [19, 24], reveal-
ing a broader functionality of tumstatin in the asthmatic airway.
Aim of this study
This study aimed to investigate the mechanism of action of tumstatin




This study aimed to investigate the effect of tumstatin on ASM-derived
ECM-dependent regulation of airway remodelling and inflammatory
response, by examining the behaviour of primary human neutrophils
and endothelial cells (human umbilical vein endothelial cells (HUVECs))
reseeded onto the decellularized ECM from non-asthmatic (NA) or asth-
matic (A) ASM cells treated with tumstatin or vehicle control. Real-time
(RT) PCR arrays were used to assess alterations in ASM-ECM induced
by tumstatin. MMP protein expression and activity along with the use
of a broad-spectrum MMP inhibitor were used to assess the role of
active MMPs in tumstatin-induced matrix remodelling.
The key methods and materials used in this study are briefly outlined
below. Full details of all methodologies are provided in the online
supplement. Information about all the patient derived lung samples used
in this study is provided in table S1.
Tumstatin gene expression by unstimulated
primary ASM, lung fibroblasts, lung endothelial
cells and airway epithelial cells
Tumstatin gene (COL4A3) expression was assessed in unstimulated NA
and A ASM cells, primary lung fibroblasts, primary lung endothelial cells
and primary airway epithelial cells from healthy individuals. Exon speci-
fic primers for COL4A3 exon 48—exon 49 boundary were used (for-
ward TCATGTCCAGAGGGGACAGT; reverse CCATGTTCATTGGCATCAGA).
ASM cell Treatment
Recombinant human tumstatin
ASM cells were treated with 50 lg/ml recombinant human tumstatin.
Tumstatin was produced and purified from E. coli colonies as previously
described [25]. Dialysis buffer from the purification process was used
as a vehicle control, which contained equal amounts of endotoxin.
Pre-treatment with broad MMP inhibitor
Marimastat (Santa Cruz Biotechnology Inc., Dallas, TX, USA), a broad
MMP inhibitor was reconstituted in DMSO and used in some experi-
ments at 100 lM to pre-treat cells for 1 hr at 37°C prior to tum-
statin treatment. The marimastat was maintained throughout the
tumstatin treatment.
ECM bioactivity assays
Chemotaxis of neutrophils seeded onto the decellularized
ASM-ECM
Neutrophils migration was assessed using a l-slide (IBIDI, Munich,
Germany) coated with the decellularized ECM of tumstatin or vehicle-
treated NA and A ASM cells. Neutrophil migration was monitored rel-
ative to a IL-8 chemoattractant gradient (100 pg/ml in RPMI with
0.5% (w/v) BSA and 2% (w/v) HEPES. A channel coated with
0.001% (w/v) fibronectin acted as a positive control. Neutrophils
were imaged every 30 sec. for 1 hr. For individual neutrophils the
pathlength, amount of movement towards IL-8, as well as movement
directionality and velocity over the ASM-ECM were extracted with a
Matlab MATLAB algorithm [26, 27]. For all experiments 265 neu-
trophils from five donors and 459 neutrophils from five donors were
assessed on the ECM of tumstatin- or vehicle-treated NA ASM cells,
respectively. On the tumstatin- or vehicle-treated A ASM-ECM 107
and 82 neutrophils were assessed, respectively, both from three
donors.
HUVEC behaviour on the decellularized ASM-ECM
Human umbilical endothelial cells were seeded onto ECM of tumstatin-
treated NA and A ASM cells, and proliferation and metabolic activities
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were assessed after 72 hrs using CyQUANT and MTT as per manufac-
turer’s guidelines (Life Technologies, Grand Island, NY, USA and
Sigma-Aldrich, St. Louis, MO, USA, respectively). HUVEC attachment to
the ASM-ECM for 30 min. was assessed with toluidine blue staining
[28]. HUVECs chemotaxis towards VEGF (10 ng/ml) was performed in a
transwell system [29]. Migrating cells were stained with toluidine blue
and manually counted. These assays were validated by examining
HUVEC behaviours on tissue culture surfaces coated with 1 lg/ml fibro-
nectin or gelatin.
Results
Tumstatin is not intrinsically expressed by ASM,
but is expressed by fibroblasts, endothelial cells
and airway epithelial cells
Tumstatin (COL4A3) gene expression was not detectable by untreated
NA and A ASM (Fig. S1; N = 2 for both groups). Fibroblasts
expressed tumstatin at the gene level at baseline (3.03  0.04
expression relative to GAPDH, N = 2). Likewise, primary lung
endothelial cells and primary airway epithelial cells also expressed
tumstatin under non-stimulatory conditions (2.29  0.13 and
1.66  0.14 expression relative to GAPDH respectively, N = 2 and 2).
Tumstatin suppressed the neutrophil chemotaxis
across asthmatic but not non-asthmatic ASM-
derived matrices
Neutrophil movement towards IL-8 over the ECM from tumstatin-
treated ASM was observed over 1 hr, and recorded on video [Exam-
ple video files from S1. Non-asthmatic ASM cell vehicle-induced
matrix; S2. Asthmatic ASM cell vehicle-induced matrix; S3. Non-asth-
matic ASM cell tumstatin-induced matrix; S4. Asthmatic ASM cell
tumstatin-induced matrix are provided in the online supplement. The
trajectories of individual neutrophils were tracked and characterized
(Fig. S2)]. Tumstatin treatment of A ASM cells created an ECM which
had no effect on neutrophil movement path length (Fig. 1A;
87.6  3.4 units versus the tumstatin vehicle 84.4  4.0 units) nor
x-fmi (amount of forward movement towards IL-8; Fig. 1B;
0.09  0.02 units versus vehicle 0.14  0.04 units) but signifi-
cantly suppressed both neutrophil velocity (Fig. 1C 2.1  0.09 units
versus vehicle 2.8  0.14 units, P < 0.001) and directionality of neu-
trophil chemotaxis (ability to move in a straight trajectory; Fig. 1D
0.30  0.019 units versus 0.4  0.027 units, P < 0.001). The
obscure, circular trajectories of neutrophils on the tumstatin-induced
A ASM-ECM can be seen in Figure S2C, compared with movement
along the A ASM-ECM generated when exposed to the vehicle control
(Fig. S2A). Interestingly distance moved by neutrophils over the tum-
statin-induced ECM from NA ASM cells was enhanced (Fig. 1A;
83.0  2.3 units versus vehicle 65.0  1.7 units, P < 0.001), as
was movement towards IL-8 (Fig. 1B; 0.097  0.020 units versus
vehicle 0.15  0.013 units, P < 0.01). The velocity of movement
of neutrophils on the tumstatin-induced NA ECM was unchanged
(Fig. 1C 2.4  0.088 units versus vehicle 2.5  0.048 units); how-
ever, directionality was decreased (Fig. 1D 0.37  0.016 units versus
vehicle 0.42  0.0098 units, P < 0.01).
The path length travelled by neutrophils on the vehicle-treated A
ASM-ECM was significantly greater than those on the vehicle-treated
NA ASM-ECM (Fig. 1A), whilst there were no differences in the x-fmi,
velocity nor directionality of neutrophils on the vehicle-treated NA or
A ASM-derived matrices (Fig. 1B–D, respectively). These findings
suggest a targeted ability of tumstatin to specifically regulate the
inflammatory potential of the A ASM-derived matrix.
Tumstatin changes the angiogenic potential of
the non-asthmatic and asthmatic ASM-ECM
The ECM deposited by A and NA ASM in the presence of the vehicle
control did not induce differences in the behaviour of HUVECs seeded
on these matrices in terms of the metabolic activity, attachment nor
migration (Fig. S3A–C). The A ASM-ECM induced greater HUVEC pro-
liferation than the NA ECM (Fig. S3D), reflecting the properties of the
A ASM-ECM previously reported for the induction of ASM cell prolif-
eration [2]. Given the similarities in the characteristics of the matrices
under basal conditions, we elected to analyse the influence of tum-
statin on the ASM-induced matrices as a percentage of the relevant
vehicle control to allow comparisons of responses relative to each cell
lines’ own baseline, enabling the examination of the overall response
pattern between A and NA deposited matrices, whilst taking into
account the heterogeneity of the baseline values between the different
cell lines (Fig. 2).
The effect that tumstatin-induced ASM-ECM remodelling had on
the angiogenic potential of the ECM was examined by seeding
HUVECs on the tumstatin-treated ASM-ECMs. The presence of tum-
statin at the time of ECM deposition affected the angiogenic prop-
erties of both the NA and A ASM-derived matrices. Tumstatin
induced an ECM from NA ASM cells, but not A ASM cells, that
increased HUVEC metabolic activity (NA: 135.7  5.8% vehicle;
N = 11, P < 0.01. A: 129.2  15.3% vehicle, N = 9, Fig. 2A). Both
the NA and A ASM-ECM became more adhesive following treatment
with tumstatin (NA: 118.8  7.0%vehicle; N = 8, P < 0.05. A:
115.2  4.3% vehicle; N = 10, P < 0.05, Fig. 2B), whilst the tum-
statin-treated A ASM-ECM, but not the NA ASM-ECM, impaired
HUVEC migration (NA: 114.3  21.0% vehicle, N = 11, A:
51.1  5.2% vehicle, N = 6; P < 0.05, Fig. 2C). The tumstatin-
treated NA ASM-ECM induced greater HUVEC proliferation, whilst
there was no change in the proliferative response on the A ASM-
ECM (NA: 130.9  13.5% vehicle, N = 4; P < 0.01. A:
113.9  3.3% vehicle, N = 5, Fig. 2D). There were no differences
in the proliferative response between A and NA tumstatin-induced
ASM-ECM, reflecting the higher basal proliferation on the A ASM-
ECM (Figs 2D and S3D). These data support the hypothesis that
restoration of tumstatin in the asthmatic airways may be effective
in mitigating aberrant angiogenesis.
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Tumstatin stimulates different genes patterns in
non-asthmatic and asthmatic ASM cells
To explain the shift in the anti-inflammatory and anti-remodelling
potential of ASM-derived ECM following tumstatin treatment, we
characterized the gene expression patterns of ECM proteins, adhesion
molecules and angio-regulatory molecules in NA and A ASM cells fol-
lowing a 24-hrs treatment with tumstatin using RT-PCR arrays. Of the
80 genes investigated 57 were differentially regulated by tumstatin
treatment in NA and A ASM cells compared the vehicle control
(Figs 3A and B; raw data Table S2). NA ASM cells showed increased
expression of 19 (33.3% of all genes) genes, whilst A ASM cells
expressed 18 (31.6%) genes higher (Fig. 3A and B, respectively).
Almost half the genes regulating inflammation and angiogenesis were
up-regulated (CEACAM-1, COL4A3, ICAM-1, IL-8, ITGA2, PRL,
MMP1, MMP10, CXCL10, VCAM-1) or down-regulated (KIT, SEMA3F,
TIE1) in both NA and A ASM in response to tumstatin (Table S2).
These data suggest a common ASM response to tumstatin, although











































































































































































Fig. 1 Tumstatin induced an ECM that suppressed neutrophil movement. Migration of neutrophils seeded on the ECM of tumstatin- or vehicle-treated
NA (N = 4–5) or A ASM (N = 3) to IL-8 was assessed over 1 hr. The path length (A), degree of direct movement to IL-8 (x-fmi; B), velocity (C)
and straightness of the neutrophil movement (directionality; D) were assessed with MATLAB by tracking the movement of individual neutrophils.
Data represented as mean and 5–95% percentiles. Groups were compared using a Mann–Whitney test, with **P < 0.01, ***P < 0.001, and
****P < 0.0001. A, asthmatic; ASM, airway smooth muscle; ECM, extracellular matrix; IL, interleukin; NA, non-
asthmatic; x-fmi, forward movement index in the direction of IL-8.
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ICAM-1, ITGA2, MMP1, MMP10, VCAM-1, KIT). The more interesting
data lay in the differentially expressed genes (Figs 3C, D and
Table S2). Genes with greater expression in NA ASM include inflam-
matory (IFNB1, TNF) and pro-angiogenic (MDK, PF4, PROK1) cytoki-
nes and growth factor receptors (KDR, NCAM) some of which
showed >150-fold difference in expression (Table S2). Conversely,
the most highly up-regulated genes in A ASM include pro- (ANGPTL4,
TGFA) and anti- (LECT1) angiogenic growth factors, and granulocyte
chemoattractants (CSF3; Table S2). In addition, in A ASM tumstatin
treatment decreased genes not expressed in NA ASM. These genes
included potent angiogenic inducers (ANGPT1, ANGPTL3, PDGFB),
matrix proteins (THBS3, COL15A1), cell-cell (SELL) and cell matrix
(LYVE1) interactions (Table S2). Overall the reduction of pro-angio-
genic proteins and factors recruiting pro-resolving macrophages may
be why the effects of tumstatin restore homeostasis to asthmatic air-
ways.
Validation of the top 8 differentially expressed genes (Figs 4, 5,
and S4) revealed that only MMP1 (Fig. 4A) and MMP10 (Fig. 5A)
were differentially expressed in the cohort of individual ASM samples.
Interestingly tumstatin only increased MMP1 and MMP10 levels in
NA ASM cells not A ASM cells, at both the gene and protein levels
[MMP-1: Gene: Fig. 4A; 4.2  1.3-fold change from vehicle, N = 8,
P < 0.01. Protein: Fig. 4B; 178.7  25.5% vehicle, N = 7, P < 0.05.
MMP-10: Gene: Fig. 5A; 10.5  4.7-fold change from vehicle, N = 7,
P < 0.05. Protein: Fig. 5B; 266.7  86.7% vehicle, N = 7,
P < 0.05). As the other genes identified in the RT-PCR arrays were
not validated in the larger patient cohort, and they were not character-














































































































Fig. 2 Tumstatin differentially regulates the angiogenic potential of ECM from NA and A ASM cells. HUVECs were seeded on the decellularized ECM
of tumstatin- or vehicle-treated NA (N = 4–11) or A ASM cells (N = 5–10). Metabolic activity (A), attachment (B), chemotaxis of HUVECs through
the ECM (C) and proliferation (D) were assessed. Data represent mean  S.E.M. and analysed using Wilcoxon and Mann–Whitney tests, with
*P < 0.05, and **P < 0.01. A, asthmatic; ASM, airway smooth muscle; ECM, extracellular matrix; HUVECs, human umbilical vein endothelial cells;
NA, non-asthmatic.
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Fig. 3 Tumstatin induced different gene expression patterns from NA and A ASM cells. The expression of genes involved in ECM remodelling and
angiogenesis in NA (N = 3–7) and A ASM (N = 3–8) was assessed with RT-PCR arrays. Genes were determined to have high ( red) or low (
green) levels of expression when showing a ≥ 1.5 fold change (positive or negative respectively) compared to vehicle control. Genes with ≤1.5 fold
change were considered to have levels of expression unchanged from baseline ( yellow), whilst other genes were not detectable in the ASM cells
( black). The proportion of genes with high, low or baseline levels of expression following treatment of NA (A) and A (B) ASM cells with tumstatin.
Venn diagrams demonstrate the number of common genes with high (C) or low (D) levels of expression in the NA and A ASM after exposure to
tumstatin. A, asthmatic; ASM, airway smooth muscle; ECM, extracellular matrix; NA, non-asthmatic; RT-PCR, real-time PCR. [Colour figure can be
viewed at wileyonlinelibrary.com]
Fig. 4 Tumstatin induces MMP-1 from NA but not A ASM cells. (A) MMP-1 mRNA expression in NA (N = 8) and A (N = 4) ASM cells by tumstatin
compared to the vehicle control. (B) MMP-1 protein was measured in the conditioned media from NA (N = 7) or A (N = 7) ASM cells treated with
tumstatin or the vehicle control. Data are represented as mean  S.E.M. of fold change from vehicle or % vehicle, and analysed using a Wilcoxon
test, and the tumstatin-treated NA and A ASM were compared with a Mann–Whitney U-test with *P < 0.05 and ***P < 0.001. A, asthmatic; ASM,
airway smooth muscle; MMP, matrix metalloproteinase; NA, non-asthmatic; RT-PCR, real-time PCR.
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Tumstatin alters the angiogenic potential of the
ASM-ECM by utilizing active ASM-derived MMPs
To examine the role of active MMPs in tumstatin-driven matrix
remodelling on the angiogenic potential of ASM-ECM, we pre-incu-
bated NA and A ASM cells with the broad-spectrum MMP inhibitor
Marimastat (100 lM) prior to tumstatin and examined the angio-
genic potential of the ECM produced. Proliferation of HUVECs on
ECM from tumstatin-treated NA ASM cells was unaffected by Mari-
mastat (Fig. 6A; tumstatin 130.9  13.5%, N = 4, Marimastat pre-
treatment 125.0  1.1% appropriate vehicle, N = 3), whilst Mari-
mastat reversed the increased metabolic activity of HUVECs on the
tumstatin-treated NA ASM-ECM (Fig. 6B; tumstatin 89.8  3.6%,
N = 11, Marimastat pre-treatment 137.5  5.8% appropriate vehi-
cle, N = 4, P < 0.001). The tumstatin induced increase in adhe-
siveness of the NA ASM-ECM was reversed in the presence of the
MMP inhibitor (Fig. 6C NA: tumstatin 118.8  7.0%, N = 8, Mari-
mastat pre-treatment 98.5  2.9% appropriate vehicle, N = 3, A:
tumstatin 104.3  1.9% N = 10, Marimastat pre-treatment
115.2  4.3% appropriate vehicle, N = 5). On the matrices from
the tumstatin-treated A ASM the proliferation and adhesion were
reversed by pre-treatment with Marimastat (Proliferation: Fig. 6A;
Marimastat pre-treatment 108.7  7.4% appropriate vehicle,
N = 5. Adhesion: Fig. 6C; Marimastat pre-treatment 104.8  1.9%
appropriate vehicle, N = 5). These data indicate that the
mechanism by which tumstatin drives ASM-derived ECM
remodelling is only partly through the use of active MMPs.
Discussion
Tumstatin is a matrikine not detectable in asthmatic airway tissues
but which is present in airway tissues of people without asthma.
When introduced to animal models of asthma tumstatin resolves fea-
tures of airway remodelling and inflammation and improves lung
function [19, 24]. The current study characterized the role of
tumstatin in the maintenance of airway tissue homeostasis, through
regulation of the ASM-derived ECM, and the potential contribution of
the absence of tumstatin in asthmatic airways to the pathogenesis.
Tumstatin induces an ASM-derived-ECM, which provides a microen-
vironment with anti-inflammatory and anti-angiogenic characteristics.
Tumstatin gene expression was detected in primary lung fibrob-
lasts, endothelial cells and airway epithelial cells, but not in primary
ASM cells. This reflects the distribution of tumstatin protein, we have
previously reported in human lung tissue [19]. Given the absence of
tumstatin production by ASM cells, this study investigated the exoge-
nous effects of this matrikine that is potentially released from the
non-asthmatic ECM to regulate tissue homeostasis.
Through the examination of neutrophil movement across matrices
from ASM cells exposed to tumstatin, the role of tumstatin in regulat-
ing the inflammatory properties of the airway wall ECM microenviron-
ment was investigated. When reintroduced to A ASM cells, tumstatin
induced an ECM which disrupted neutrophil motility, slowing the rate
and decreasing the ability of neutrophils to move purposefully
towards a chemoattractant. This, to our knowledge, is the first illus-
tration of the ECM providing directional cues for neutrophil migration
in asthmatic lung. Similar disruptions in neutrophil movement were
seen on the tumstatin-induced NA ASM-ECM, in addition to a
decrease in the purposeful movement, or directionality of the neu-
trophils despite increased pathlength. Neutrophils use cell-surface
receptors and integrins to transmigrate through the endothelial cell
layer and identify, attach to, and migrate through the localized tissue
[30]. The influence of the tissue ECM on neutrophil infiltration
remains poorly understood. It is known that neutrophil proliferation is
enhanced by fibrinogen [31] and survival increased by fibronectin and
laminin [32]. Laminin enhances protease release from neutrophils
and neutrophil chemotaxis [33] potentiating inflammatory cell move-
ment. The current study findings suggest tumstatin has the potential
to create an anti-inflammatory microenvironment, which inhibits neu-
trophils in the airway tissue.
The bioactive properties of tumstatin-induced ASM-ECM were
assessed further, by examining the angio-regulatory properties of the
Fig. 5 Tumstatin-induced MMP-10 from NA but not A ASM cells. (A) MMP-10 mRNA expression by NA (N = 7) and A (N = 3) ASM cells in
response to tumstatin was compared to the vehicle control. (B) MMP-10 protein was measured in the conditioned media from NA (N = 7) or A
(N = 7) ASM cells treated with tumstatin or the vehicle control. Data are represented as mean  S.E.M. of fold change from vehicle or % vehicle,
and analysed using a Wilcoxon test, and the tumstatin-treated NA and A ASM were compared with a Mann–Whitney U-test with *P < 0.05 and
***P < 0.001. A, asthmatic; ASM, airway smooth muscle; MMP, matrix metalloproteinase; NA, non-asthmatic; RT-PCR, real-time PCR.
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ASM-ECM following exposure to tumstatin. Tumstatin induced an
ECM from NA and A ASM cells capable of differential regulation of
endothelial cell behaviour. The tumstatin-stimulated NA ASM cell
microenvironment increased the proliferation, metabolic activity and
attachment of endothelial cells, whilst the ECM from tumstatin-treated
A ASM cells enhanced endothelial cell attachment but impaired move-
ment. Blood vessel expansion, specifically the process of vessel
sprouting, requires the formation of a highly specific and motile dif-
ferentiated tip cell and the proliferation of stalk cells [1, 34]. In vivo,
the tip cells must begin migration before the proliferation of the stalk
cells is purposeful. The consequence of the increased attachment and
decreased chemotaxis of endothelial cells on the tumstatin-treated
ASM-matrices would be the failure of sprout formation. The subse-
quent limitation of new tubule formation combined with the
ASM-ECM would hence hamper the angiogenic process. Thus, an
anti-angiogenic matrix was deposited from both NA and A ASM cells
in the presence of tumstatin.
Changes to the bioactive properties of the ECM can result from
matrix remodelling. Proteases, once released and activated, act on
the ECM, altering the structure, composition and thus biological func-
tion. Two proteases, MMP-1 and -10, were expressed highly in NA
ASM cells following tumstatin treatment. The use of the broad-spec-
trum MMP inhibitor in this study which inhibited the tumstatin-
induced NA ASM-ECM enhanced metabolic activity and proliferation,
suggested these proteases were partly responsible for the anti-angio-
genic properties that tumstatin induced in the NA ASM-ECM. These
data are in concert with earlier observations of MMPs regulating
inflammatory properties of the ECM. MMP9-overexpressing trans-
genic mice exhibited altered leucocyte extravasation and reduced lym-
phocyte accumulation in the airway walls [35]. In addition, in our
Fig. 6 Tumstatin regulated the angiogenic potential of ASM-derived ECM by utilizing active MMPs. HUVECs seeded on the ECM of NA (N = 4–11) or
A ASM (N = 5–9) cells treated with vehicle, or tumstatin  Marimastat, were measured for proliferation (A), metabolic activity (B), attachment (C),
migration (D). Data represent the mean  S.E.M. of the change from the vehicle control and analysed using a Kruskal–Wallis test with *P < 0.05,
**P < 0.01 and ***P < 0.001. A, asthmatic; ASM, airway smooth muscle; ECM, extracellular matrix; HUVECs, human umbilical vein endothelial
cells; NA, non-asthmatic.
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study tumstatin altered the expression of a number of genes, from
both NA and A ASM cells, involved in MMP activation (such as SER-
PIN B5), although the gene expression patterns were different, and
experiments were not carried out to validate gene array findings.
ASM gene expression in the presence or absence of tumstatin
was assessed broadly with RT-PCR arrays, exploring tumstatin’s
effect on genes involved in ECM remodelling and angiogenesis. There
were a number of common genes induced or reduced in the NA and A
ASM cells following tumstatin treatment, suggested a core response
in healthy and diseased ASM to this matrikine. One significant exam-
ple is the large increase in expression of collagen IV a3 (COL4A3)
induced by tumstatin in both NA and A ASM cells. This gene encodes
for the parent protein of tumstatin, suggesting reintroduction of tum-
statin into the airway tissue initiates a positive feedback loop increas-
ing the release of the active matrikine. These strong positive feedback
systems, in addition to the therapeutic anti-inflammatory and anti-
remodelling effects of tumstatin in vitro and in vivo, hint at the vital
role of tumstatin for airway homeostasis.
Implications of this study
This study provides new knowledge enabling a better understanding
of the beneficial anti-remodelling and anti-inflammatory effects of
tumstatin when administered to the lungs. This study elucidates a
mechanism through which tumstatin modulates the ECM microenvi-
ronment as a broad influential regulator of multiple cell types and cell
behaviours. Tumstatin drives specific characteristics of the ASM-ECM
that may control the expansion of the airway vasculature and inflam-
matory cell influx in the airway tissue. This study expands previous
reports of tumstatin as a potential asthma therapeutic.
Acknowledgements
Human lung tissue was obtained in collaboration with the transplant coordina-
tors, respiratory specialists, surgeons, nurses and pathology staff of St. Vin-
cent’s Hospital, Sydney; the respiratory specialists, surgeons, nurses and
pathology staff, Royal Prince Alfred Hospital, Concord Hospital, Strathfield Pri-
vate Hospital and Douglas H Moir Pathology. Umbilical cords were collected
by the obstetricians and research midwives at Royal North Shore Hospital.
Gyde Nissen of the University of Lubeck optimized the neutrophil isolation and
chemotaxis experiments.
Funding Source: This work was supported by a grant from The National
Health and Medical Research Council (Fellowship 1032695 to JKB), The
University of Groningen and the European Union (Rosalind Franklin Fellowship
to JKB), the Group of 8 Exchange Program, DAAD (to JKB and MW) and the
Asthma Foundation NSW (to LMH).
All authors contributed to the design of this project. LMH and MW con-
ducted experiments, T Becker developed the cell tracking algorithm and all
authors analysed and interpreted the data. All authors contributed to the prepa-
ration of this manuscript.
Conflict of interest
The authors have no competing interests to report related to the pro-
duction of these data or the preparation of this manuscript.
Supporting information
Additional Supporting Information may be found online in the
supporting information tab for this article:
Figure S1 Primary lung endothelial cells, airway fibroblasts and air-
way epithelial cells express tumstatin.
Figure S2 Tumstatin induces A but not NA ASM cells to deposit an
ECM which disrupts the movement of neutrophils.
Figure S3 HUVECS respond similarly to NA and A ASM-ECM depos-
ited in the presence of tumstatin vehicle.
Figure S4 Validation of genes expressed by NA and A ASM cells in
response to tumstatin.
Video S1 Nonasthmatic airway smooth muscle cell vehicle-induced
matrix.
Video S2 Asthmatic airway smooth muscle cell vehicle-induced
matrix.
Video S3 Nonasthmatic airway smooth muscle cell tumstatin-induced
matrix.
Video S4 Asthmatic airway smooth muscle cell tumstatin-induced
matrix.
Appendix S1 Materials and methods.
Table S1 Information of samples used in this study.
Table S2 Tumstatin differentially regulates gene expression pat-
terns in NA and A ASM cells.
References
1. Hutchings H, Ortega N, Plouet J. Extracellu-
lar matrix-bound vascular endothelial growth
factor promotes endothelial cell adhesion,
migration, and survival through integrin liga-
tion. FASEB J. 2003; 17: 1520–2.
2. Johnson PR, Burgess JK, Underwood PA,
et al. Extracellular matrix proteins modulate
asthmatic airway smooth muscle cell prolif-
eration via an autocrine mechanism. J
Allergy Clin Immunol. 2004; 113: 690–6.
3. Johnson PR. Role of human airway smooth
muscle in altered extracellular matrix pro-
duction in asthma. Clin Exp Pharmacol Phys-
iol. 2001; 28: 233–6.
3296 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
4. Harkness LM, Ashton AW, Burgess JK.
Asthma is not only an airway disease, but
also a vascular disease. Pharmacol Thera-
peut. 2015; 148: 17–33.
5. Boulet LP, Laviolette M, Turcotte H, et al.
Bronchial subepithelial fibrosis correlates
with airway responsiveness to methacholine.
Chest. 1997; 112: 45–52.
6. Bousquet J, Jeffery PK, Busse WW, et al.
Asthma. From bronchoconstriction to air-
ways inflammation and remodeling. Am J
Respir Crit Care Med. 2000; 161: 1720–45.
7. Mastalerz L, Kasperkiewicz H. Effect of
inhaled corticosteroids on small airway inflam-
mation in patients with bronchial asthma. Pol
Arch MedWewn. 2011; 121: 264–9.
8. Woodruff PG, Khashayar R, Lazarus SC,
et al. Relationship between airway inflam-
mation, hyperresponsiveness, and obstruc-
tion in asthma. J Allergy Clin Immunol.
2001; 108: 753–8.
9. Barnes PJ, Adcock IM. How do corticos-
teroids work in asthma? Ann Intern Med.
2003; 139: 359–70.
10. Chanez P, Wenzel S. Severe asthma. Presse
medicale. 2008; 37: 99–105.
11. Hew M, Chung KF. Corticosteroid insensitivity
in severe asthma: significance, mechanisms
and aetiology. Intern Med J. 2010; 40: 323–34.
12. McDonald VM, Gibson PG. Exacerbations of
severe asthma. Clin Exp Allergy. 2012; 42:
670–7.
13. Busse WW, Lemanske RF Jr. Asthma. N
Engl J Med. 2001; 344: 350–62.
14. Ollerenshaw SL, Woolcock AJ. Characteris-
tics of the inflammation in biopsies from
large airways of subjects with asthma and
subjects with chronic airflow limitation. Am
Rev Respir Dis. 1992; 145: 922–7.
15. Pandya NM, Dhalla NS, Santani DD. Angio-
genesis—a new target for future therapy.
Vascul Pharmacol. 2006; 44: 265–74.
16. Goldie RG, Pedersen KE. Mechanisms of
increased airway microvascular permeabil-
ity: role in airway inflammation and obstruc-
tion. Clin Exp Pharmacol Physiol. 1995; 22:
387–96.
17. Schoonbrood DF, Lutter R, Habets FJ, et al.
Analysis of plasma-protein leakage and local
secretion in sputum from patients with
asthma and chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 1994;
150: 1519–27.
18. Roberts CR, Burke AK. Remodelling of the
extracellular matrix in asthma: proteoglycan
synthesis and degradation. Can Resp J.
1998; 5: 48–50.
19. Burgess JK, Boustany S, Moir LM, et al.
Reduction of tumstatin in asthmatic airways
contributes to angiogenesis, inflammation,
and hyperresponsiveness. Am J Respir Crit
Care Med. 2010; 181: 106–15.
20. Hardingham TE, Fosang AJ. Proteoglycans:
many forms and many functions. FASEB J.
1992; 6: 861–70.
21. Bourdoulous S, Orend G, MacKenna DA,
et al. Fibronectin matrix regulates activa-
tion of RHO and CDC42 GTPases and cell
cycle progression. J Cell Biol. 1998; 143:
267–76.
22. Hamano Y, Kalluri R. Tumstatin, the NC1
domain of [alpha]3 chain of type IV collagen,
is an endogenous inhibitor of pathological
angiogenesis and suppresses tumor growth.
Biochem Biophys Res Comm. 2005; 333:
292–8.
23. Campbell NE, Kellenberger L, Greenaway
J, et al. Extracellular matrix proteins and
tumor angiogenesis. J Oncol. 2010; 2010:
doi: 10.1155/2010/586905.
24. Van der Velden J, Harkness LM, Barker DM,
et al. The effects of tumstatin on vascularity,
airway inflammation and lung function in an
experimental sheep model of chronic asthma.
Sci Rep. 2016; 6: doi:10.1038/srep26309.
25. Faiz A, Tjin G, Harkness L, et al. The
expression and activity of cathepsins D, H
and K in asthmatic airways. PLoS One.
2013; 8: e57245.
26. Rapoport DH, Becker T, Madany Mamlouk
A, et al. A novel validation algorithm allows
for automated cell tracking and the extrac-
tion of biologically meaningful parameters.
PLoS One. 2011; 6: e27315.
27. Weckmann M, Becker T, Nissen G, et al.
SiMA: a simplified migration assay for analyz-
ing neutrophil migration. Cytometry. 2017. in
press 29 March 2017.
28. Moir LM, Black JL, Krymskaya VP. TSC2
modulates cell adhesion and migration via
integrin-alpha1beta1. Am J Physiol Lung Cell
Mol Physiol. 2012; 303: L703–10.
29. Ashton AW, Ware JA. Thromboxane A2
receptor signaling inhibits vascular endothe-
lial growth factor-induced endothelial cell
differentiation and migration. Circ Res.
2004; 95: 372–9.
30. Padmanabhan J, Gonzalez AL. The effects
of extracellular matrix proteins on neu-
trophil-endothelial interaction–a roadway to
multiple therapeutic opportunities. Yale J
Biol Med. 2012; 85: 167–85.
31. Luscinskas FW, Brock AF, Arnaout MA,
et al. Endothelial-leukocyte adhesion mole-
cule-1-dependent and leukocyte (CD11/
CD18)-dependent mechanisms contribute
to polymorphonuclear leukocyte adhesion
to cytokine-activated human vascular
endothelium. J Immunol. 1989; 142:
2257–63.
32. Ginis I, Faller DV. Protection from apopto-
sis in human neutrophils is determined by
the surface of adhesion. Am J Physiol. 1997;
272: C295–309.
33. Adair-Kirk TL, Atkinson JJ, Broekelmann
TJ, et al. A site on laminin alpha 5, AQAR-
SAASKVKVSMKF, induces inflammatory cell
production of matrix metalloproteinase-9
and chemotaxis. J Immunol. 2003; 171:
398–406.
34. Arroyo AG, Genis L, Gonzalo P, et al. Matrix
metalloproteinases: new routes to the use of
MT1-MMP as a therapeutic target in angio-
genesis-related disease. Curr Pharm Des.
2007; 13: 1787–802.
35. Mehra D, Sternberg DI, Jia Y, et al. Altered
lymphocyte trafficking and diminished air-
way reactivity in transgenic mice expressing
human MMP-9 in a mouse model of asthma.
Am J Physiol Lung Cell Mol Physiol. 2010;
298: L189–96.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
3297
J. Cell. Mol. Med. Vol 21, No 12, 2017
